Suppr超能文献

相似文献

3
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25.
5
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7.
6
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
United European Gastroenterol J. 2019 Nov;7(9):1189-1197. doi: 10.1177/2050640619873784. Epub 2019 Sep 3.
7
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1750-1757.e3. doi: 10.1016/j.cgh.2016.11.023. Epub 2016 Nov 24.
8
Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 2024 Apr;78(4):853-861. doi: 10.1002/jpn3.12132. Epub 2024 Jan 25.
9
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
Aliment Pharmacol Ther. 2018 Apr;47(7):906-912. doi: 10.1111/apt.14548. Epub 2018 Jan 31.
10
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
United European Gastroenterol J. 2019 Jul;7(6):741-749. doi: 10.1177/2050640619840211. Epub 2019 Mar 19.

引用本文的文献

4
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study.
J Can Assoc Gastroenterol. 2024 Mar 24;7(4):290-298. doi: 10.1093/jcag/gwae010. eCollection 2024 Aug.
6
Approach to loss of response to advanced therapies in inflammatory bowel disease.
World J Gastroenterol. 2024 Jun 14;30(22):2902-2919. doi: 10.3748/wjg.v30.i22.2902.
7
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Medicina (Kaunas). 2024 Jan 31;60(2):250. doi: 10.3390/medicina60020250.
8
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach.
Indian J Gastroenterol. 2024 Feb;43(1):93-102. doi: 10.1007/s12664-024-01527-z. Epub 2024 Feb 8.
10
The Role of Therapeutic Drug Monitoring in Children.
Gastroenterol Clin North Am. 2023 Sep;52(3):549-563. doi: 10.1016/j.gtc.2023.05.002. Epub 2023 Jun 9.

本文引用的文献

2
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.
7
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25.
8
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
Aliment Pharmacol Ther. 2018 Apr;47(7):906-912. doi: 10.1111/apt.14548. Epub 2018 Jan 31.
9
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7.
10
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053. doi: 10.1111/apt.14368. Epub 2017 Oct 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验